Olema Pharmaceuticals/$OLMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Ticker
$OLMA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
102
ISIN
US68062P1066
Website
OLMA Metrics
BasicAdvanced
$318M
-
-$1.95
2.04
-
Price and volume
Market cap
$318M
Beta
2.04
52-week high
$16.62
52-week low
$2.86
Average daily volume
898K
Financial strength
Current ratio
15.219
Quick ratio
15.141
Long term debt to equity
0.032
Total debt to equity
0.299
Profitability
EBITDA (TTM)
-147.359
Management effectiveness
Return on assets (TTM)
-27.44%
Return on equity (TTM)
-41.59%
Valuation
Price to book
0.83
Price to tangible book (TTM)
0.83
Price to free cash flow (TTM)
-2.466
Free cash flow yield (TTM)
-40.55%
Free cash flow per share (TTM)
-188.56%
Growth
Earnings per share change (TTM)
-3.87%
3-year earnings per share growth (CAGR)
-0.68%
What the Analysts think about OLMA
Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.
Bulls say / Bears say
Olema Pharmaceuticals' lead drug, palazestrant, demonstrated a median progression-free survival of 13.8 months in combination with ribociclib for ER+/HER2- metastatic breast cancer patients, indicating strong clinical efficacy. (stocktitan.net)
Major institutional investors, including Bain Capital Life Sciences and Avoro Capital Advisors, have significantly increased their holdings in Olema Pharmaceuticals, reflecting confidence in the company's future prospects. (mayfieldrecorder.com, marketbeat.com)
Analysts from firms like Oppenheimer and J.P. Morgan have maintained 'Buy' ratings on Olema Pharmaceuticals, citing promising clinical data and strategic drug positioning. (markets.businessinsider.com)
Olema Pharmaceuticals' stock has experienced a significant decline, reaching a 52-week low of $3.86, reflecting investor concerns over the company's financial performance. (investing.com)
The company reported a net loss of $30.4 million in Q1 2025, indicating ongoing financial challenges that may impact future operations. (stocktitan.net)
Despite promising clinical results, the lengthy timelines for Phase 3 trials and potential commercial launch in 2027 may delay revenue generation, posing a risk to short-term financial stability. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
OLMA Financial Performance
Revenues and expenses
OLMA Earnings Performance
Company profitability
OLMA News
AllArticlesVideos
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Olema Pharmaceuticals stock?
Olema Pharmaceuticals (OLMA) has a market cap of $318M as of July 13, 2025.
What is the P/E ratio for Olema Pharmaceuticals stock?
The price to earnings (P/E) ratio for Olema Pharmaceuticals (OLMA) stock is 0 as of July 13, 2025.
Does Olema Pharmaceuticals stock pay dividends?
No, Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders as of July 13, 2025.
When is the next Olema Pharmaceuticals dividend payment date?
Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Olema Pharmaceuticals?
Olema Pharmaceuticals (OLMA) has a beta rating of 2.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.